David Rosenfeld, MD
Interventional Pain Medicine · Covington, GANPI 1861435364
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $165,416 of the $248,576 with a category attached, or 66.5%. 60 manufacturers reported payments, led by Trevena, Inc. at 24.4% of the total. Among interventional pain medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,085 payments — averaging $229.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Trevena, Inc.$61K
- Biotronik NRO, Inc.$54K
- Daiichi Sankyo Inc.$33K
- Abbott$21K
- Baudax Bio Inc.$16K
- Acelrx Pharmaceuticals, Inc.$13K
- plus $49K from 54 others
Across 23 payments — averaging $1679.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Saluda Medical Americas, Inc.$18K
- Boston Scientific$14K
- Nalu Medical, Inc.$6K
What the payments were for
- Consulting fees$19,3148%
- Speaking & faculty fees$165,41667%
- Travel & lodging$30,90912%
- Food & beverage$31,98713%
- Education$9210%
- Gifts$150%
- Entertainment$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Olinvyk$60,006
- Prospera$50,697
- Morphabond ER$32,653
- ANJESO$16,010
- PROCLAIM$13,654
- DSUVIA$13,091
- Lucemyra/Lofexidine$4,516
- LUCEMYRA$3,850
- Zilretta$3,375
- Proclaim Family of SCS IPGs$2,291
- Roxybond$1,875
- SACROILIAC JOINT FUSION SYSTEM$1,696
- SPECTRA WAVEWRITER$1,638
- SYNCHROMED$1,409
- PRIALT$1,330
- Proclaim IPG$1,248
- Prolate$1,230
- SiFix$1,200
- AIMOVIG$1,066
- Evoke SCS$914
How this compares
$248,576 in reported general payments places this provider in the 95th percentile of 129 interventional pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 122 | $102,411 |
| Xtampza ErOxycodone Myristate | 151 | $82,009 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,127 | $62,445 |
| OxycontinOxycodone Hcl | 75 | $61,791 |
| RelistorMethylnaltrexone Bromide | 20 | $46,853 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,420 | $29,840 |
| ZtlidoLidocaine | 24 | $26,266 |
| Buprenorphine | 92 | $26,113 |
| MovantikNaloxegol Oxalate | 42 | $19,195 |
| Oxycodone Hcl | 822 | $18,398 |
| NucyntaTapentadol Hcl | 13 | $17,238 |
| Morphine Sulfate ErMorphine Sulfate | 409 | $10,986 |
| Oxymorphone Hcl ErOxymorphone Hcl | 12 | $10,773 |
| Pregabalin | 436 | $8,081 |
| Gabapentin | 483 | $5,422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta | $1,101 | $201,659286 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $908 | $46,85320 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $519 | $26,26624 claims |
| Redhill Biopharma Inc.Movantik | $41 | $19,19542 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 129 interventional pain medicine providers in Georgia.
Other interventional pain medicine in Covington
- Rhee MillerCovington$17K
- Emmanuel GageBrunswick$602K
- Jordan TateJasper$540K
- Christopher BovinetBrunswick$338K
- Nathan NeufeldNewnan$171K
- Ryan BudwanyLawrenceville$123K
- Alexandra MoreiraAtlanta$79K
- Sushanth BodaNewnan$55K
- Christopher AndrianoStockbridge$41K
- Guensley DelvaWaycross$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.